Publications

Lymph node metastasis predicts disease recurrence in a single-center experience of 70 stages 1–3 appendix cancers: a retrospective review

GM Nash, JD Smith, L Tang, MR Weiser, LK Temple, E O’Reilly, LB Saltz, ...

nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT).

MA Tempero, DB Cardin, A Biankin, D Goldstein, M Moore, EM O'Reilly, ...

Novel directions in neoadjuvant therapy for pancreas adenocarcinoma

A Yang, EM O’Reilly

Novel therapeutics for pancreatic adenocarcinoma

MA Lowery, EM O'Reilly

Overall survival and clinical characteristics in BRCA mutation carriers with stage I/II pancreatic cancer (PC).

T Golan, T Sella, MM Javle, A Borgida, EM O'Reilly, DP Kelsen, ...

P-185 Randomized phase III trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant therapy for patients with resected pancreatic cancer: APACT

M Tempero, D Cardin, A Biankin, D Goldstein, M Moore, E O'Reilly, ...

Phase 2 multi‐institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma

JM Herman, DT Chang, KA Goodman, AS Dholakia, SP Raman, ...

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic …

J Bendell, EM O'Reilly, MR Middleton, I Chau, H Hochster, A Fielding, ...

Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC).

MA Lowery, DP Kelsen, SC Smith, M Moore, HL Kindler, T Golan, A Segal, ...

Pilot study of vemurafenib and panitumumab combination therapy in patients with BRAF V600E mutated metastatic colorectal cancer.

RD Yaeger, A Cercek, EM O'Reilly, DL Reidy, NE Kemeny, T Wolinsky, ...

Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients

R Yaeger, A Cercek, EM O'Reilly, DL Reidy, N Kemeny, T Wolinsky, ...

Platinum-based combination therapy (PCT) and outcomes for patients (pts) with mixed hepatocellular carcinoma and intrahepatic cholangiocarcinoma (mHCC/ICC).

LC Connell, JJ Harding, MA Lowery, NE Kemeny, A Cercek, ...

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer …

EM O'Reilly, D Mahalingam, JM Roach, BC Schultes, ME Rosano, ...

The impact of chemotherapy on hospitalizations and emergency care in older adults with advanced cancer.

EB Elkin, C O'Neill, CL Atoria, EM O'Reilly, P Bach

Treatment, outcomes, and clinical trial participation in elderly patients with metastatic pancreas adenocarcinoma

D Li, M Capanu, HY Kenneth, MA Lowery, DP Kelsen, EM O'Reilly

Tu1953 Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT)

M Tempero, D Cardin, AV Biankin, D Goldstein, M Moore, E O'Reilly, ...

25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance)

K Van Loon, K Owzar, C Jiang, HL Kindler, MF Mulcahy, D Niedzwiecki, ...

465 Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P+ Gem) demonstrates …

A Kapoun, E O'Reilly, A Cohn, JC Bendell, L Smith, JH Strickler, W Gluck, ...

A 39-year-old female patient with metastatic rectal cancer develops thrombocytopenia

H Dbouk, S Mentha, D Mukherji, J Lee, A Haydar, A Shamseddine, ...

A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma

GK Abou-Alfa, M Capanu, EM O’Reilly, J Ma, JF Chou, B Gansukh, J Shia, ...

A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic …

D Li, S Pant, DP Ryan, D Laheru, N Bahary, T Dragovich, PJ Hosein, ...

A single-arm, non-randomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma

EM O'Reilly, A Perelshteyn, WR Jarnagin, M Schattner, H Gerdes, ...

A woman with metastatic pancreatic neuroendocrine tumor

AN Shoushtari, AM Covey, G Zaatari, A Shamseddine, AS Epstein, ...

APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients …

MA Tempero, DB Cardin, A Biankin, D Goldstein, M Moore, EM O'Reilly, ...

APACT: A Phase III Trial of Nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) Versus Gem Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (PC): 232

M Tempero, D Cardin, A Biankin, D Goldstein, M Moore, E O’Reilly, ...

APACT: a Phase III Trial of nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) vs Gem Alone as Adjuvant Therapy for Patients (pts) with Resected Pancreatic Cancer (PC)

MA Tempero, D Cardin, A Biankin, D Goldstein, M Moore, EM O'Reilly, ...

APACT: A phase III trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone for resected pancreatic cancer (PC)

MA Tempero, D Cardin, A Biankin, D Goldstein, M Moore, EM O'Reilly, ...

Chemotherapy and Intensity Modulated Radiation Therapy for Locally Advanced Pancreatic Cancer Achieves Prolonged Survival

C Hajj, F Huguet, A Wu, W Shi, Z Zhang, E O'Reilly, C Winston, D Reidy, ...

DNA mismatch repair abnormalities in acinar cell carcinoma of the pancreas: frequency and clinical significance

W Liu, J Shia, M Gönen, MA Lowery, EM O’Reilly, DS Klimstra

Embolization versus embolization and systemic therapy in patients with hepatocellular carcinoma and metastatic disease: A retrospective analysis.

S Kim, KT Brown, Y Fong, SB Solomon, JF Chou, M Capanu, JJ Harding, ...

Evaluation of PARP inhibition as a platinum sparing strategy in Brca2-deficient pancreatic tumors.

MA Lowery, A Lee, E Tobias, P Sung, U Bhanot, R Shakya, T Ludwig, ...

Final Results of a Phase 1B of Omp-59R5 (Anti-Notch2/3/Stem Cell Antibody) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P+ Gem) in Patients (Pts) with Untreated …

J Bendell, AL Cohn, L Smith, JH Strickler, WL Gluck, WG Schmidt, ...

FOLFIRINOX induction therapy for stage III pancreatic adenocarcinoma

E Sadot, A Duossot, EM O'Reilly, M Gönen, TP Kingham, MI D'Angelica, ...

Gemcitabine-related pneumonitis: Elucidation of risk factors.

IH Sahin, A Geyer, D Kelly, EM O'Reilly

Lymph node ratio is an independent prognostic factor after resection of periampullary malignancies: data from a tertiary referral center in the middle East

AI Shamseddine, D Mukherji, C Melki, E Elias, M Eloubeidi, H Dimassi, ...

Molecular features of BRCA1/2 and PALB2 mutation associated pancreatic cancer (PAC).

MA Lowery, K Timms, V Abkevich, C Neff, A Gutin, JS Lanchbury, ...

Multiplatform molecular profiling of 2,400 pancreatic adenocarcinomas to identify targets for therapeutic intent.

SZ Millis, D Arguello, MA Lowery, EM O'Reilly

Multiplatform profiling of a fibrolamellar carcinoma cohort.

JJ Harding, SZ Millis, EM O'Reilly, L Saltz, GK Abou-Alfa, AP Venook, ...

Outcomes of biliary stents in advanced pancreatic cancer in the era of improved systemic therapy.

W Park, PK Mankal, EM O'Reilly

Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer

KH Yu, M Ricigliano, M Hidalgo, GK Abou-Alfa, MA Lowery, LB Saltz, ...

Pharmacogenomic modeling of pancreatic cancer (PDAC) for prediction of chemotherapy response and resistance in second-line treatment setting.

KH Yu, V Sangar, M Ricigliano, M Hidalgo, EM O'Reilly, GK Abou-Alfa, ...

Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+ Gem) in patients (pts) with untreated metastatic …

EM O'Reilly, LS Smith, JC Bendell, FA Rangwala, W Schmidt, ...

Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC).

EM O'Reilly, MA Lowery, MF Segal, SC Smith, MJ Moore, HL Kindler, ...

The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on …

T Seufferlein, JL Van Laethem, E Van Cutsem, JD Berlin, M Büchler, ...

Treatment of Metastatic Pancreatic Adenocarcinoma: New Options and Promising Strategies.

MA Lowery, EM O'REILLY

Treatment, outcomes, and clinical trial participation in very elderly patients (pts) with metastatic pancreas cancer (mPC).

D Li, M Capanu, KH Yu, MA Lowery, DP Kelsen, EM O'Reilly

25-hydroxyvitamin D levels and survival in patients with advanced pancreatic cancer (APC): Findings from CALGB 80303.

K Van Loon, K Owzar, C Jiang, HL Kindler, MF Mulcahy, D Niedzwiecki, ...

A giant rectal villous adenoma with a malicious intent

MA Hosn, N Abdel-Hafiez, R Abdel-Wahab, A Al-Ahmadie, A Antar, ...

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas

JK Lee, M Capanu, EM O'reilly, J Ma, JF Chou, J Shia, SS Katz, ...

A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients

AS Epstein, AE Volandes, LY Chen, KA Gary, Y Li, P Agre, TT Levin, ...